regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
However, the mass of an atomic-scale object is affected by the binding energy of the nucleons in its atomic nuclei, as well as the mass and binding energy of its electrons. Therefore, this equality holds only for the carbon-12 atom in the stated conditions, and will vary for other substances. For example, the mass of an unbound atom of the common hydrogen isotope (hydrogen-1, protium) is 1.007825032241(94) Da, the mass of a proton is 1.0072764665789(83) Da, the mass of a free neutron is 1.00866491606(40) Da, and the mass of a hydrogen-2 (deuterium) atom is 2.014101778114(122) Da. In general, the difference (absolute mass excess) is less than 0.1%; exceptions include hydrogen-1 (about 0.8%), helium-3 (0.5%), lithium-6 (0.25%) and beryllium (0.14%). The dalton differs from the unit of mass in the system of atomic units, which is the electron rest mass (me).
== Chemistry == Flmodafinil is a racemic mixture of (S)-(+)- and (R)-(–)-enantiomers. The (S)-(+) enantiomer has been referred to as JBG1-048 and the (R)-(–) enantiomer has been referred to as JBG1-049.
== History == The disorder was first described in 1959 by psychiatrist and researcher Albert Stunkard as "night eating syndrome" (NES). The term "binge eating" was coined to describe the same bingeing-type eating behavior but without the exclusive nocturnal component. There is less research on BED than there is on anorexia or bulimia.
Iron-deficiency anemia may be present without a person experiencing symptoms. It tends to develop slowly; therefore, the body has time to adapt, and the disease often goes unrecognized for some time. If symptoms present, patients may present with the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), and the symptoms of feeling tired, weak, dizziness, lightheadedness, poor physical exertion, headaches, decreased ability to concentrate, cold hands and feet, cold sensitivity, increased thirst and confusion. None of these symptoms (or any of the others below) are sensitive or specific. In severe cases, shortness of breath can occur. Pica may also develop; of which consumption of ice, known as pagophagia, has been suggested to be the most specific for iron deficiency anemia. Other possible symptoms and signs of iron-deficiency anemia include:
=== October === 1 October The price of an average energy bill rises by £149 per year to £1,717. Buckingham Palace announces that Princess Beatrice of York is expecting her second child. A new law requires hospitality sector workers in England, Wales and Scotland to receive all money from tips left by customers. 2 October – The first flight chartered by the UK government to evacuate British nationals from Lebanon following the increase in tension between Hezbollah and Israel arrives in the UK with 150 people on board. 3 October – The UK announces that it will give up sovereignty of the Chagos Islands to Mauritius, subject to finalisation of a treaty. 4 October A Royal Navy investigation finds that women in the Submarine Service have faced misogyny, bullying and other unacceptable behaviour. First Sea Lord Admiral Sir Ben Key, who heads the Royal Navy, apologises and describes such behaviour as "intolerable". The UK government pledges £22bn in investment over the next 25 years for projects to capture and store carbon emissions from energy, industry and hydrogen production. Data published by the Independent Schools Council, the body representing private schools in the UK, indicates a 4.6% fall in the number of private students starting in private sector secondary education in September 2024. 395 migrants cross the English Channel in small boats from France to the UK. 5 October A large pro-Palestinian protest, involving tens of thousands of marchers, takes place in central London, coinciding with the first anniversary of the 7 October attacks.
Sources: en.wikipedia.org
Dipicolinic acid (pyridine-2,6-dicarboxylic acid or PDC and DPA) is a chemical compound which plays a role in the heat resistance of bacterial endospores. It is also used to prepare dipicolinato ligated lanthanide and transition metal complexes for ion chromatography.
Cotadutide is an experimental drug for the treatment of type 2 diabetes mellitus. It lowers blood glucose levels by mimicking the human hormones glucagon-like peptide 1 and glucagon, which play a role in blood sugar regulation. The drug is a peptide that is injected under the skin. Cotadutide is in Phase II clinical trials as of February 2021. Cotadutide, a therapeutic agent, was undergoing Phase II clinical trials. This stage of trials typically involves evaluating the drug's effectiveness and further assessing its safety in a larger group of participants, compared to earlier phases.
Due to the wide range of causes of camptocormia, there is no one treatment that suits all patients. In addition, there is no specific pharmacological treatment for primary BSS. The use of analgesic drugs depends entirely on the intensity of the back pain. Muscular-origin BSS can be alleviated by positive lifestyle changes, including physical activity, walking with a cane, a nutritious diet, and weight loss. Worsening of symptoms is possible but rare in occurrence. Treatment of the underlying cause of the disease can alleviate the condition in some individuals with secondary BSS. Other treatment options include drugs, injections of botulinum toxin, electroconvulsive therapy, deep brain stimulation, and surgical correction. Unfortunately, many of the elderly individuals affected by the BSS are not treated surgically due to age-related physical ailments and the long postoperative recovery period.
==== 3100–3199 ==== Credit Unions (Authorised Investments) Order 1993 (S.I. 1993/3100) Education (Schools Conducted by Education Associations) (Initial Articles of Government) Regulations 1993 (S.I. 1993/3101) Education (Grant-maintained Schools) (Initial Governing Instruments) Regulations 1993 (S.I. 1993/3102) Education (Schools Conducted by Education Associations) Regulations 1993 (S.I. 1993/3103) Education (Application of Financing Schemes to Special Schools) Regulations 1993 (S.I. 1993/3104) Education (School Curriculum and Assessment Authority) (Orders for Transfer of Property and Staff) Order 1993 (S.I. 1993/3105) Education Act 1993 (Commencement No. 2 and Transitional Provisions) Order 1993 (S.I. 1993/3106) Education (School Government) (Amendment) Regulations 1993 (S.I. 1993/3107) Local Government (Compensation for Premature Retirement) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3108) Insurance Companies (Pension Business) (Transitional Provisions) (Amendment) Regulations 1993 (S.I. 1993/3109) Stamp Duty Reserve Tax (Amendment) Regulations 1993 (S.I. 1993/3110) Friendly Societies (Modification of the Corporation Tax Acts) (Amendment) Regulations 1993 (S.I. 1993/3111) Friendly Societies (Provisional Repayments for Exempt Business) Regulations 1993 (S.I. 1993/3112) Education (Publication of School Proposals and Notices) Regulations 1993 (S.I. 1993/3113) Education Assets Board (Transfers under the Education Reform Act 1988) (Amendment) Regulations 1993 (S.I.
In return, the host provides the symbiont with chemicals required for chemosynthesis, such as carbon, sulfide, and oxygen. In the early stages of studying life at hydrothermal vents, there were differing theories regarding the mechanisms by which multicellular organisms were able to acquire nutrients from these environments, and how they were able to survive in such extreme conditions. In 1977, it was hypothesized that the chemoautotrophic bacteria at hydrothermal vents might be responsible for contributing to the diet of suspension-feeding bivalves. Finally, in 1981, it was understood that giant tubeworm nutrition acquisition occurred as a result of chemoautotrophic bacterial endosymbionts. As scientists continued to study life at hydrothermal vents, it was understood that symbiotic relationships between chemoautotrophs and macrofauna invertebrate species was ubiquitous. For instance, in 1983, clam gill tissue was confirmed to contain bacterial endosymbionts; in 1984 vent bathymodiolid mussels and vesicomyid clams were also found to carry endosymbionts. However, the mechanisms by which organisms acquire their symbionts differ, as do the metabolic relationships. For instance, tubeworms have no mouth and no gut, but they do have a "trophosome", which is where they deal with nutrition and where their endosymbionts are found. They also have a bright red plume, which they use to uptake compounds such as O, H2S, and CO2, which feed the endosymbionts in their trophosome.
Sources: en.wikipedia.org
African American Cultural Complex Contemporary Art Museum of Raleigh Gregg Museum of Art & Design at North Carolina State University Haywood Hall House & Gardens Marbles Kids Museum North Carolina Museum of Art North Carolina Museum of History North Carolina Museum of Natural Sciences North Carolina Sports Hall of Fame City of Raleigh Museum J. C. Raulston Arboretum Joel Lane House Mordecai Plantation Pope House Museum
==== United Kingdom ==== Estimates show that in 2024 there were nearly a million people living with AD and other dementias in the UK, with more than 800,000 in England. This is expected to rise to 1.4 million by 2040. In 2022 and 2023, dementia was the leading cause of death in England and Wales.
== External links == Clinical trial number NCT05118789 for "A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)" at ClinicalTrials.gov
Meristematic tissue consists of actively dividing cells and leads to an increase in length and thickness of the plant. The primary growth of a plant occurs only in certain specific regions, such as in the tips of stems or roots. It is in these regions that meristematic tissue is present. Cells of this type of tissue are roughly spherical or polyhedral to rectangular in shape, with thin cell walls. New cells produced by meristem are initially those of meristem itself, but as the new cells grow and mature, their characteristics slowly change and they become differentiated as components of meristematic tissue, being classified as: { 1.Primary meristem.
== In germline cells == In 1957, André and Rouiller first coined the term "nuage". (French for "cloud"). Its amorphous and fibrous structure occurred in drawings as early as in 1933 (Risley). Today, the nuage is accepted to represent a characteristic, electrondense germ plasm organelle encapsulating the cytoplasmic face of the nuclear envelope of the cells destined to the germline fate. The same granular material is also known under various synonyms: dense bodies, mitochondrial clouds, yolk nuclei, Balbiani bodies, perinuclear P granules in Caenorhabditis elegans, germinal granules in Xenopus laevis, chromatoid bodies in mice, and polar granules in Drosophila. Molecularly, the nuage is a tightly interwoven network of differentially localized RNA-binding proteins, which in turn localize specific mRNA species for differential storage, asymmetric segregation (as needed for asymmetric cell division), differential splicing and/or translational control. The germline granules appear to be ancestral and universally conserved in the germlines of all metazoan phyla. Many germline granule components are part of the piRNA pathway and function to repress transposable elements.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.